miRNA-130a Targets ATG2B and DICER1 to Inhibit Autophagy and Trigger Killing of Chronic Lymphocytic Leukemia Cells

Valentina Kovaleva, Rodrigo Mora, Yoon Jung Park, Christoph Plass, Abhilash I. Chiramel, Ralf Bartenschlager, Hartmut Döhner, Stephan Stilgenbauer, Armin Pscherer, Peter Lichter, and Martina Seiffert

Abstract
Toxicity and relapses from the immunochemotherapy used to treat chronic lymphocytic leukemia (CLL) prompt continued interest in gentle but effective targeted treatment options for the main elderly population suffering from this disease. Here, we report the definition of critical CLL cell survival pathways that can be targeted by ectopic reexpression of the miRNA genes miR-130a and miR-143, which are widely downregulated in CLL. Notably, miR-130a inhibited autophagy by reducing autophagosome formation, an effect mediated by downregulation of the genes ATG2B and DICER1, the latter of which is a major component of the miRNA silencing machinery. In support of the concept of a fundamental connection between miRNA disregulation and altered autophagic flux in this cancer, we showed that RNA interference–mediated knockdown of DICER1 expression was sufficient to reduce autophagy in primary or established cultures of CLL cells. Together, our findings show that miR-130a modulates cell survival programs by regulating autophagic flux, and they define roles for miR-130a and Dicer1 in a regulatory feedback loop that mediates CLL cell survival.

Introduction
B-cell chronic lymphocytic leukemia (CLL) is characterized by the expansion of CD5+/CD19+/CD23+ B lymphocytes and shows diverse pathogenic mechanisms and a heterogeneous clinical course (1, 2). Inherent defects in cell death of CLL B lymphocytes that are nourished by a small proliferative pool in lymph nodes, spleen, and bone marrow are responsible for the massive accumulation of malignant cells. Prolonged CLL cell survival is induced by autocrine signaling pathways and survival stimuli from the microenvironment (3, 4).

Authors' Affiliations: 1Molecular Genetics; 2Integrative Bioinformatics and Systems Biology; 3Epigenomics and Cancer Risk Factors, German Cancer Research Center; 4Department for Infectious Diseases - Molecular Virology, University of Heidelberg, Heidelberg; 5Internal Medicine III, University of Ulm, Ulm, Germany; and 6Department of Nutritional Science and Food Management, College of Health Science, Ewha Womans University, Seoul, Republic of Korea

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Current address for R. Mora: Department of Medical Virology, Faculty of Microbiology, University of Costa Rica, San Pedro, Costa Rica.


Corresponding Author: Peter Lichter, German Cancer Research Center, Department for Molecular Genetics, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Phone: 49-6221-42-4619; Fax: 49-6221-42-4639; E-mail: peter.lichter@dkfz.de
doi: 10.1158/0008-5472.CAN-11-3671
©2012 American Association for Cancer Research.
in CLL cells in vitro (17) and might therefore enhance the efficacy of drugs currently used for CLL treatment.

In this study, we investigate the effects of 5 miRNAs that are downregulated in CLL on the regulation of cell death/cell survival programs. We show that enforced expression of miR-130a impairs cell viability and inhibits autophagic flux in CLL cells, suggesting a new miRNA-autophagy regulatory axis for modulating survival mechanisms in CLL cells.

Materials and Methods

**Cell lines**

HEK293T and HS-5 cells were purchased from American Type Culture Collection and retested and authenticated in 02.2011 and 05.2008, respectively. MEC-1 cells were obtained from DSMZ (Braunschweig, Germany) in 2009 and not passaged longer than 6 months continuously. Cells were cultured in Dulbecco’s Modified Eagle’s Medium (Invitrogen) supplemented with 10% fetal calf serum (Biochrom) and 1% penicillin/streptomycin (Gibco BRL, Invitrogen; referred to as complete medium) at 37°C and 10% CO2.

**Primary cells**

Peripheral blood (PB) samples were collected from CLL patients (Supplementary Table S1) and healthy donors after informed consent. All cases matched standard diagnostic criteria (18). Mononuclear cells were isolated and cultured as reported before (19).

**RNA and DNA isolation**

Total RNA with or without miRNA fraction was isolated with miRNeasy or RNeasy Mini Kit, respectively (QIAGEN). Genomic DNA was isolated with Blood & Cell Culture DNA Midi Kit (QIAGEN).

**miRNA expression analysis**

Total RNA (700 ng) was employed for miRNA expression analysis using bead-based miRNA expression assay (Illumina). The array data were analyzed by BeadStudio v3.2 software (Illumina) and are available at the National Center for Biotechnology Information Gene Expression Omnibus (GEO) database, accession no. GSE31599. For further validation of miRNA expression, quantitative real-time PCR (qRT–PCR) analysis was carried out by TaqMan MicroRNA Assays (Applied Biosystems).

**miRNA precursor molecules, miRNA inhibitors, and siRNAs**

All synthetic miRs and anti-miRs including Negative Control pre-miRNA (AM17110) and Negative Control anti-miR Inhibitor (AM17010) were purchased from Applied Biosystems. Silencer Select Negative Control siRNA (4390843) and DICERI siRNA (s23755) were obtained from Applied Biosystems.

**Nucleofection of cell lines and primary CLL cells**

A total of $1 \times 10^7$ primary B cells were transfected with the human B-cell Nucleofector Kit and program U-015 with 1 μmol/L miRNA or siRNA according to the manufacturer’s instructions (Lonza). After nucleofection, primary cells were cultured in 4 mL of sterile filtered conditioned medium obtained from HS-5 cell cultures. Transfection of MEC-1 cells was carried out by nucleofection (solution V, program X-001) with $5 \times 10^6$ cells and 0.5 μmol/L miRNA or siRNA and subsequent culture in complete medium.

**Construction of DICER1 and ATG2B 3’ untranslated region luciferase plasmids and reporter assay**

The 3’ untranslated region (UTR) fragments of DICER1 and ATG2B containing the miRNA target sites were amplified from MEC-1 genomic DNA by PCR using FastStart Taq DNA Polymerase (Roche Diagnostics) and the primers listed in Supplementary Table S2. PCR products were cloned into pMIRREPORT luciferase plasmid (Applied Biosystems) using HindIII and SpeI restriction sites. For reporter assays, 1 $\times 10^5$ HEK293T cells were cotransfected with 5 ng of 3’UTR reporter plasmid, 50 ng pRL-TK Renilla luciferase reporter vector (Promega), and 30 nmol/L miR-130a or Negative Control miRNA using TransIT transfection reagent, according to the manufacturer’s instructions (Mirus BioLLC). Transfected cells were lysed 36 hours after transfection and luciferase activities were assayed by a Dual-Luciferase Reporter System (Promega).

**Cell viability analysis**

Cell viability was assessed by flow cytometry after Annexin V–phycocerythrin (PE) and 7-aminoactinomycin D (7-AAD) staining (BD Biosciences) as described before (20). Double-negative cells were counted as viable cells. Fluorescence-activated cell sorting (FACS) analyses were carried out with a FACScanto II flow cytometer equipped with FACSDiva V6.1.2 software (BD Biosciences).

**qRT-PCR**

For mRNA quantification, total RNA was isolated from cells 48 hours after transfection and transcribed with SuperScript II and anchored oligo-d(T)$_20$ primer (Invitrogen). Amplification and quantification of cDNA was carried out with SYBR Green ROX Mix (Agene, Episome) according to the manufacturer’s protocol and as described before (20). qRT-PCR was carried out in 7900 HT Fast Real-Time PCR System (Applied Biosystems). Relative quantification was done in relation to 2 housekeeping genes (LAMINB1 and PGK1). The qRT-PCR primer sequences are listed in Supplementary Table S2.

**Western blotting**

Cells were harvested 48 hours after transfection and lysed in 50 mmol/L Tris-HCl, pH 7.5; 150 mmol/L NaCl; 1% NP-40, containing Complete Mini protease inhibitor mixture (Roche Diagnostics). Protein extracts were electrophoresed on 4% to 12% linear gradient Bis-Tris ready gels (Invitrogen) and transferred to Immobilon-P polyvinylidene fluoride membranes (Millipore). Membranes were probed with antibodies specific for Dicer1 (1:1,000, ab14601; Abcam), LC3-B (1:1,000, 2775 S; Cell Signaling, Inc.), α-tubulin (1:2,500; Sigma Aldrich), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:2,500, CB1001; Calbiochem), and subsequently with horseradish peroxidase–coupled anti-rabbit or anti-mouse antibodies (both...
Specific bands were visualized with ECL Blotting Detection Reagents (Amersham Biosciences) and quantified with Image J software.

**Generation of MEC-1/GFP-LC3 cells**

To generate a stable cell line expressing GFP-LC3 fusion protein, MEC-1 cells were transduced with the pWPI lentiviral vector containing the GFP-LC3 sequence, using a titer of 2.6 × 10^6 for 5 × 10^5 cells and selected in the presence of puromycin (Invitrogen) for 2 weeks.

**Imaging of autophagic flux**

Autophagic flux was quantified by an imaging flow cytometer (ImageStream, Amnis) employing 2 × 10^6 MEC-1/GFP-LC3 cells per analyzed sample. For starvation, cells were transferred to Krebs-Henseleit buffer (Sigma-Aldrich) 24 hours after transfection and incubated for further 8 hours in the presence or absence of 100 nmol/L lysosomal H1-ATPase inhibitor bafilomycin A1 (Merck KGaA). Subsequently, cells were harvested and resuspended in 100 μL of cold PBS/2% bovine serum albumin. To exclude dead cells from the analysis, TO-PRO3 (quinolinium, 4-[3-(3-methyl-2(3H)-benzothiazolyl)propyl]-1-[3-(trimethylammonio)propyl], diiodide; Invitrogen) was added directly before acquisition at a final concentration of 1 μmol/L. For each sample, images of 5,000 cells were acquired in the bright field channel and the fluorescence emission channels at 660 nm (TO-PRO-3) and 520 nm (GFP). The acquired images were analyzed with IDEAS software (Amnis) as described in Supplementary Material. The statistical significance of the differences between the autophagic flux distributions was assessed using a Kolmogorov-Smirnov test. In addition, the histogram channels of the autophagic flux distribution presenting a significant difference in frequencies were evidenced by the Student t test (see Supplementary Material for details).

**Results**

**A set of miRNAs is downregulated in CLL**

Previous studies have reported that the majority of miRNAs are downregulated in CLL when compared with normal B cells (21). To identify deregulated miRNAs, we carried out miRNA expression profiling on RNA samples of 18 CLL patients and on pooled RNA of PB B lymphocytes of 5 healthy donors by miRNA arrays. MiR-126, miR-130a, miR-143, miR-181a, and miR-326 were among the top 20 downregulated miRNAs in CLL patients (GEO no. GSE31599). To confirm this finding, we quantified the respective miRNAs by qRT-PCR in samples of 6 CLL patients. Both methods showed lower expression levels of these 5 miRNAs in CLL cells compared with normal B cells and qRT-PCR values ranged from 1.5- to approximately 20-fold reduction (Fig. 1).

To elucidate whether the lower expression levels of these miRNAs in CLL is due to epigenetic transcriptional silencing, we assessed the methylation status of putative miRNA promoter regions by MassArray. Out of the tested miRNAs, only miR-126 showed a significant gain in methylation within its predicted transcriptional start site in CLL cells compared with healthy B-cell control (P = 0.007; Supplementary Fig. S1). Small subsets of patients showed hypermethylation of miR-326 and miR-181a, but the average methylation values were not significantly different compared with the controls. This result indicates that the majority of the tested sequences are not affected by epigenetic regulation, and aberrant methylation is not the main reason for the deregulated expression of the studied miRNAs in our CLL patient cohort. However, we cannot rule out that other, not yet identified miRNA regulating sequences are under the influence of epigenetic regulation.

**miR-130a and miR-143 induce cell death in CLL cells**

To investigate the function of the underrepresented miRNAs in CLL, we first assessed their impact on cell viability because accumulation of quiescent CLL cells is primarily due to defects in apoptosis induction, rather than increased cell proliferation as reflected in gene expression (22, 23). Freshly isolated CLL cells were transiently transfected with one of the following synthetic miRNAs: miR-126, miR-130a, miR-143, miR-181a, miR-326, or with an unspecific miRNA used as negative control (NC). Cell viability was measured 48 hours after transfection by flow cytometry after Annexin V–PE/7-AAD staining. Introduction of miR-130a, miR-143, and miR-181a led to an average reduction in the number of viable cells of 21%, 15%, and 23% respectively, when compared with the NC set as 100% viability (P miR-130a = 0.01; P miR-143 = 0.02; P miR-181a = 0.03; Fig. 2A). Furthermore, we tested whether the above-mentioned 5 miRNAs have an impact on the viability of the CLL cell line MEC-1. Twenty-four hours after transfection of miR-130a or miR-143, the number of viable MEC-1 cells was decreased by 57% or 50%, respectively, when compared with unspecific miRNA control (P miR-130a = 0.001; P miR-143 = 0.001; Fig. 2B). MiR-181a slightly, though not significantly, reduced cell viability of MEC-1 cells, whereas miR-126 and miR-326 did not affect viability of either primary or cell line CLL cells. These results indicate that miR-130a and miR-143 induce cell death both in primary CLL and MEC-1 cells.
**Autophagy is induced in CLL cells under starvation**

We next sought to investigate the mechanism of how miR-130a and miR-143 impact survival-related pathways in CLL. Autophagy is one possible mechanism of how cancer cells overcome cellular stress and maintain cell survival and resistance to apoptosis (11). To investigate the relevance of autophagy in CLL cell survival, we used chloroquine, a late stage inhibitor of autophagy, in primary CLL cultures and observed decreased cell viability in a dose-dependent manner (Supplementary Fig. S2), which confirms results published earlier (17). In addition, chloroquine treatment resulted in enhanced fludarabine-induced cell death in primary CLL cells (data not shown). To evaluate the role of autophagy in CLL cells in more detail, we followed the specific autophagosome marker LC3, a microtubule-associated protein 1 light chain 3, which is involved in the formation of autophagosomes and translocates from a soluble form, LC3-I, to the autophagosomal membrane-bound form LC3-II (24). For this means, we generated a stable MEC-1 cell line expressing GFP-tagged LC3 (MEC-1/GFP-LC3). Accumulation of fluorescent dots, representing autophagosomes, was evaluated in these cells by imaging flow cytometry as described in the Materials and Methods section. Because autophagic flux can be measured as the difference in autophagosome formation between samples in the presence or absence of inhibitors of autophagosome degradation (25), we quantified GFP-positive autophagosomes in cells treated for 8 hours with or without the lysosomal H1-ATPase inhibitor bafilomycin A1 (BaF).

In nonstress conditions, the basal level of autophagy can be very low, but might be induced upon starvation. Therefore, we determined autophagic flux in MEC-1/GFP-LC3 cells cultured in complete medium or under starvation conditions. Representative images of analyzed cells are presented in Fig. 3A, showing increased GFP-LC3 clustering in bafilomycin-treated cells under starvation conditions. The level of GFP-LC3 clustering was extracted from the individual cellular images and represented by the bright detail intensity feature (Fig. 3A, bottom). A nonparametric description derived from the Kolmogorov-Smirnov (K-S) statistics was applied for the quantification and representation of these data, as described in Supplementary Material. Briefly, we calculated the autophagic flux of MEC-1/GFP-LC3 cells as the difference in bright detail intensities between bafilomycin-treated and bafilomycin-untreated states (Fig. 3B, left and middle). The obtained data indicate that MEC-1 cells have a constitutively active autophagy in complete medium conditions, which is extensively upregulated upon starvation as indicated by the right shift of the curve (Fig. 3B, right).

Autophagy might therefore be a survival mechanism of CLL cells. All subsequent analyses of autophagic flux in MEC-1/GFP-LC3 cells were conducted under starvation conditions to obtain high assay sensitivity.

**miR-130a inhibits autophagic flux in CLL.**

To investigate the impact of miR-130a and miR-143 on autophagy in CLL cells, MEC-1/GFP-LC3 cells were transfected with these 2 synthetic miRNAs or a scrambled miRNA used as NC, and autophagic flux was analyzed. Introduction of miR-130a resulted in a robust change in the autophagic flux distributions showing lower frequencies when compared with the NC. A summary of 4 independent experiments showed statistically significant reduction of autophagosome formation (Kolmogorov-Smirnov test for each individual experiment, P < 0.05; mean histogram channels of 4 experiments with statistical difference are labeled with dots, Student t test, P < 0.05), indicating that miR-130a inhibits autophagic flux in MEC-1/GFP-LC3 cells.

![Image](cancerres.aacrjournals.org)
cells (Fig. 3C). Transfection of cells with miR-143 did not reveal statistically significant changes in the autophagic flux distribution (data not shown).

To confirm our observations by an independent assay, we conducted Western blot analysis for endogenous LC3 protein by MEC-1 cells treated under the same conditions as described above. Autophagic flux was assessed by calculating the difference of LC3-II protein of samples in the presence or absence of bafilomycin (ΔLC3-II) as reported (26). These experiments revealed decreased ΔLC3-II in miR-130a–transfected samples (Fig. 3D, left), which confirms reduced autophagic flux in MEC-1 cells upon introduction of miR-130a. We further investigated the role of miR-130a in autophagy in primary CLL cells by Western blot analysis. Similar as in MEC-1 cells, transfection of primary CLL cells with miR-130a resulted in a decrease in ΔLC3-II (Fig. 3D, right). These results show for the first time that autophagy is an active process in primary CLL cells and is regulated by miR-130a.

**DICER1 and ATG2B are direct targets of miR-130a**

To identify genes that are regulated by miR-130a, we analyzed previously reported transcriptome data and searched for
transcripts with higher expression levels in primary CLL samples compared with healthy B cells (27). These differentially expressed genes were analyzed for miR-130a binding sites by Targetscan software. By this means, DICER1 was selected as a novel potential miR-130a target gene because it was upregulated 2.3-fold in CLL cells relative to healthy donor control and has a highly conserved binding site for miR-130a. In addition, autophagy-related genes were screened for miR-130a binding sequences and thereby ATG2B, a mediator of autophagy, was identified and selected for further studies. The miR-130a binding site within the 3’ UTR of DICER1 is conserved between human, mouse, rat, dog, and chicken; and of ATG2B between human, dog, and chicken (Fig. 4A).

To examine miR-130a-mediated regulation of the selected genes, we transfected primary CLL cells with synthetic miR-130a and assessed DICER1 and ATG2B mRNA levels by qRT-PCR 48 hours after transfection. This resulted in a 1.4-fold reduction of DICER1 (P = 0.002) and a 1.8-fold reduction of ATG2B (P = 0.02) mRNA levels when compared with transfection with unspecific control miRNA (Fig. 4B).

Furthermore, to confirm that the downregulation of the tested mRNA is due to direct interaction between miR-130a and its predicted binding site, we cotransfected HEK293T cells with miR-130a and pMIR luciferase reporter constructs containing 3’ UTR fragments of DICER1 and ATG2B. In the presence of miR-130a, relative luciferase activity assessed 36 hours after transfection for the DICER1 and ATG2B constructs was reduced by 25% (P = 0.09) and 37% (P = 0.05), respectively (Fig. 4C). Importantly, inhibition of endogenous miR-130a by transfection of anti–miR-130a (inhibitor of miR-130a) in HEK293T cells increased the luciferase activities of reporter constructs for DICER1 and ATG2B by 10% (P = 0.05) and 33% (P = 0.03), respectively (Fig. 4C).

These results show that miR-130a downregulates DICER1 and ATG2B mRNAs by direct interaction with their 3’ UTRs and therefore identifies these genes as novel targets for miR-130a in CLL cells.

**miR-130a downregulates Dicer1 protein expression in primary CLL and MEC-1 cells**

We next assessed whether the observed regulation of DICER1 and ATG2B by miR-130a is reflected by changes on protein level. Due to the lack of ATG2B-specific antibodies, this could not be achieved for this protein so far. For Dicer1, Western blot analyses were conducted with lysates of primary CLL cells transiently transfected with miR-130a or control miRNA. Dicer1 protein levels were analyzed by quantifying the bands corresponding to full-length Dicer1 protein of 218.7 kDa, which is the upper band in the blots shown in Fig. 5A. In 3 analyzed samples of primary CLL cells, introduction of miR-130a resulted in reduced Dicer1 levels when compared with unspecific miRNA transfection (Fig. 5A). A respective experiment using B lymphocytes of a healthy donor showed reduced Dicer1 protein after miR-130a transfection in these cells as well (Fig. 5A). Furthermore, introduction of miR-130a in MEC-1 cells resulted in a downregulation of Dicer1 by 2.3-fold relative to unspecific miRNA control (Fig. 5B).

![Figure 4. DICER1 and ATG2B are direct targets of miR-130a. A, schematic representation of the 3’ UTRs of DICER1 and ATG2B indicating the fragments which were cloned into the luciferase reporter construct pMIR-REPORT. Evolutionary conserved regions containing the miR-130a binding sites are highlighted by frames in the sequence alignments of different species. B, expression level of DICER1 and ATG2B mRNA quantified by qRT-PCR 48 hours after miR-130a transfection in primary CLL cells. mRNA levels were normalized to 2 housekeeping genes (LAMINB1 and PGK1) and are presented as mean values ± SEM relative to NC results (DICER1, n = 6; ATG2B, n = 3). Paired t test was applied to assess statistical significance. P_{DICER1} = 0.002; P_{ATG2B} = 0.2. C, 3’UTR luciferase reporter assay for DICER1 and ATG2B. HEK293T cells were cotransfected with pMIR-3’UTR luciferase reporter construct and miR-130a or anti–miR-130a and respective controls (NC or anti-NC). Relative luciferase intensity was assessed as described in the Materials and Methods section and is presented as mean ± SEM of 4 independent experiments. “∗”, P ≤ 0.05.](image-url)
Knockdown of Dicer1 leads to reduced autophagy in primary CLL and MEC-1 cells

To investigate whether Dicer1 is involved in autophagy in CLL cells, we transfected Dicer1-specific siRNA in MEC-1 and primary CLL cells, which resulted in a reduction of Dicer1 protein 48 hours after transfection of around 75% and 60%, respectively. Autophagic flux was evaluated in the transfected cells in the presence and absence of bafilomycin by Western blotting of LC3 protein and revealed a considerable reduction of D-LC3-II after knockdown of Dicer1 both in MEC-1 and primary CLL cells (Fig. 6). This suggests that inhibition of autophagy in CLL cells by miR-130a is mediated at least partly by its target gene DICER1.

Because Dicer1 is a key component of the miRNA biogenesis machinery, it was likely that downregulation of Dicer1 by miR-130a results in reduced levels of miRNAs in general. Therefore, we measured expression levels of 7 different miRNAs (miR-21, miR-26a, miR-28, miR-146a, miR-148b, miR-193b, and let-7c) after transfection of miR-130a in MEC-1 cells. This resulted in reduced expression levels of all 7 tested miRNAs (between 0.4- and 0.8-fold) compared with transfections of unspecific miRNA (data not shown). Therefore, the observed effect of miR-130a on cell survival and autophagy in CLL cells might be due to major changes in the miRNA profile of the cells.

Taken together, our data show that miR-130a regulates autophagic flux and cell viability in both MEC-1 and primary CLL cells and suggest that its target gene DICER1 is involved in this process.

Discussion

Deregulated expression of miRNAs is a common feature of many tumor entities, including CLL. Here, specific miRNA signatures were shown to differentiate patients with short and long intervals to therapy (28, 29). The biological role of most of these miRNAs in tumor development and progression is however still unclear. The aim of this study was therefore a functional analysis of 5 deregulated miRNAs in CLL, miR-126, miR-130a, miR-143, miR-181a, and miR-326, which were shown to be underrepresented in CLL cells compared with normal B cells by us and others (21). For some of these deregulated miRNAs implications in CLL biology have been suggested: miR-181a has been reported to regulate the CLL relevant oncogenes...
TCI and PLAGI (21, 30), and miR-143 which is downregulated in several B-cell malignancies, was shown to target ERK5, a mitogen–activated protein kinase protein (31).

One of the reasons for deregulated miRNA expression in cancer is promoter silencing due to aberrant DNA methylation. Therefore, we examined the promoter methylation status of the downregulated miRNAs in CLL patients and observed a significant increase in promoter methylation of miR-126 in comparison with normal B cells. This is again in accordance with data published by Pallasch and colleagues (21) who additionally showed a tendency for hypermethylation of the promoter regions of miR-130a, miR-181a, and miR-326.

Our primary interest was to elucidate a possible role of the downregulated miRNAs in the persistent survival of CLL cells. By miRNA transfection studies, we showed that miR-130a and miR-143 reduce viability of both primary CLL and MEC-1 cells. To investigate the molecular mechanism of how these miRNAs regulate survival of CLL cells, we proceeded with studying the role of autophagy in CLL cell survival and a possible involvement of miR-130a or miR-143 in its regulation.

Autophagy is a highly conserved prosurvival mechanism to maintain cellular homeostasis upon different types of stress and plays a crucial role in cancer. In tumor cells with defects in apoptosis, autophagy was shown to prolong cell survival (32), but the interplay between autophagy and apoptosis and its role in cancer are still poorly understood. Of crucial importance is to increase our knowledge on the regulation of autophagy in cancer with the aim to modulate autophagy in tumor cells and thereby inhibit their survival. Inhibitors of autophagy that sensitize apoptosis-resistant tumor cells to anticancer therapy are under current investigation in clinical trials (33). The potential regulation of autophagy by miRNAs may offer an efficient multitarget strategy to accomplish a robust autophagy inhibition unaffected by single target gene mutations, cell to cell heterogeneity or other hallmarks of cancer cell resistance. Some miRNAs have been reported to regulate autophagy-related genes, such as miR-30a, regulating BECN1 and miR-196, regulating IRGM (13, 14).

In both primary CLL and MEC-1 cells, we monitored autophagic flux and showed for the first time that autophagy is an active process in these cells. In addition, we showed that MEC-1 cells were able to respond to starvation by an increased autophagic flux. These data suggest that autophagy is a constitutive mechanism in CLL and is part of the stress response of these cells to the lack of nutrients. Because introduction of miR-130a and miR-143 reduced viability of both primary CLL and MEC-1 cells, we investigated their impact on autophagy. Indeed, miR-130a reduced autophagic flux in primary CLL cells and MEC-1 cells, which for the first time identified miR-130a as a regulator of autophagy in CLL. In accordance with our results, a recent systems biology–based computational analysis study reported that miR-130a is one of 5 putative miRNAs that regulate the autophagy-lysosomal pathway (34). Although, the role of miR-130a in CLL biology was unclear, in ovarian cancer miR-130a was associated with anticancer drug resistance because it was found to be downregulated in cell lines resistant to paclitaxel and cisplatin (35).

To further elucidate the molecular mechanism of miR-130a–mediated CLL cell survival and autophagy, we aimed at identifying putative target genes of this miRNA. By luciferase reporter assay, we identified the autophagy-related gene ATG2B as a direct target of miR-130a and showed downregulation of ATG2B expression in CLL cells transfected with miR-130a. ATG2B interacts with ATG2A and WDR45 and thus is possibly involved in vesicle nucleation and the initial steps of autophagosome formation (36). Interestingly, ATG2A was found to be 1.5-fold upregulated in CLL samples relative to healthy donor controls (27). Association of ATG2B and cancer has been reported: frameshift mutations were found in the mononucleotide repeats in the coding sequence of ATG2B gene in gastric and colorectal carcinomas (37). Our data imply that ATG2B might be involved in miR-130a–mediated autophagy in CLL cells. Its functional role in this process has to be further investigated.

In addition, we identified Dicer1 as a direct target gene of miR-130a and showed that knockdown of Dicer1 results in reduced autophagic flux in CLL cells. Dicer1 is a highly conserved protein, with endonuclease RNase III activity, required for siRNA- and miRNA-mediated silencing. Therefore, miR-130a is most likely involved in autophagy and cell survival in CLL cells via regulating the maturation and activity of many miRNAs, multiplying the amount of indirect effective target genes. Indeed, our results showed that reduction of Dicer1 levels by overexpression of miR-130a lead to reduced levels of several miRNAs in CLL cells. The effects of miR-130a in CLL cells might therefore be mediated by a more global change in the miRNA profile of the cells and the presence of feedback loops involving Dicer1 and several miRNAs are very likely.

As a key enzyme in RNA-induced silencing, Dicer1 is essential for maintaining many crucial cellular processes including B-cell development. Koralov and colleagues showed that in the absence of Dicer1, B-cell development is almost completely blocked at the transition from pro-B to pre-B cells due to failure in response to survival signals at this early stage of development (38). Increased expression of Dicer1 has been shown in several tumor types including ovarian and prostate cancer (39, 40) and was often associated with tumor progression and poor prognosis. In addition, deletion of Dicer1 in B cells in a Myc-induced lymphoma model significantly inhibited lymphomagenesis (41).

Because the Dicer1 gene harbors a long 3′ UTR (>4,000 bp) with multiple sites for potential miRNA binding, it is likely to be targeted by several miRNAs. In addition to our data showing regulation of Dicer1 by miR-130a, the miRNA let-7 and the miR-103/107 cluster have been reported to regulate Dicer1 protein (42, 43).

Taken together, our results show that miR-130a plays a role in CLL cell death/cell survival pathways including autophagy. We identified ATG2B, as an autophagy-related target gene of miR-130a, which might be involved directly in CLL cell resistance to apoptosis. The regulatory network of miR-130a is presumably highly complex as it also targets Dicer1, an essential component of the miRNA biogenesis machinery, suggesting the presence of feedback loops and the
involvement of other miRNAs. Which miRNAs and respective target genes are essentially involved in this regulation will be of major interest on the way to identify novel drug targets. Our results also point toward a cancer-supporting role of Dicer1 in CLL because its downregulation by miR-130a leads to a decrease in autophagy and induces cell death. The understanding of these regulatory networks offers a great potential for the intelligent multitargeted design of new cancer therapies.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

References

miR-130a Regulates Autophagy in CLL

Acknowledgments
The authors thank Dr. Nathan Brady and Prof. Roland Eils, German Cancer Research Center, for the possibility to work on the imaging flow cytometer, and Sibylle Old for excellent technical assistance.

Grant Support
This study was supported by grants from the Deutsche José Carreras Leukämie-Stiftung (D)CL5 R 0613 and D)CL5 R 10/04) and a Roman Herzog research fellowship from the Hertie foundation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 6, 2011; revised January 19, 2012; accepted February 10, 2012; published OnlineFirst February 20, 2012.


miRNA-130a Targets ATG2B and DICER1 to Inhibit Autophagy and Trigger Killing of Chronic Lymphocytic Leukemia Cells

Valentina Kovaleva, Rodrigo Mora, Yoon Jung Park, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-11-3671

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2012/02/20/0008-5472.CAN-11-3671.DC1

Cited articles
This article cites 42 articles, 15 of which you can access for free at:
http://cancerres.aacrjournals.org/content/72/7/1763.full.html#ref-list-1

Citing articles
This article has been cited by 14 HighWire-hosted articles. Access the articles at:
/content/72/7/1763.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.